Yestar Healthcare Holdings Co (HKSE:02393) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Yestar Healthcare Holdings Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Yestar Healthcare Holdings Co Valuation Rank Related Terms

Yestar Healthcare Holdings Co Business Description

Address No. 1, Lane 388, Kang’an Road, Room 1210-1213, 12th Floor, Building T1, Pudong New District, Shanghai, CHN
Yestar Healthcare Holdings Co Ltd is engaged in the manufacture, distribution, and sale of medical imaging products, distribution of In Vitro Diagnostic (IVD) products, and manufacture and sale of dental films. The Group has two reportable operating segments: Imaging printing products segment, which includes the manufacture and sale of colour photographic paper, industrial NDT x-ray films and PWB films, and trading of imaging equipment; and Medical products and equipment segment, which generates maximum revenue and includes manufacture and sale of medical dry films, medical wet films and dental films, and sale of medical equipment and diagnostic reagents. The Group operates its business in Mainland China.